{"title": "Orientaci\u00f3n conjunta sobre la vacunaci\u00f3n contra COVID-19 y el manejo de la osteoporosis", "author": null, "url": "https://www.osteoporosis.foundation/news/orientacion-conjunta-sobre-la-vacunacion-contra-covid-19-y-el-manejo-de-la-osteoporosis", "hostname": "osteoporosis.foundation", "description": "Orientaci\u00f3n conjunta sobre la vacunaci\u00f3n contra COVID-19 y el manejo de la osteoporosis de la American Society for Bone and Mineral Research (ASBMR), American Association of Clinical Endocrinology (AACE), Endocrine Society, European Calcified Tissue Society (ECTS), International Osteoporosis Foundation (IOF), y la National Osteoporosis Foundation (NOF)", "sitename": "International Osteoporosis Foundation", "date": "2021-03-11", "id": null, "license": null, "body": null, "comments": "", "commentsbody": null, "raw_text": null, "text": "\u00daltimas noticias\nOrientaci\u00f3n conjunta sobre la vacunaci\u00f3n contra COVID-19 y el manejo de la osteoporosis de la American Society for Bone and Mineral Research (ASBMR), American Association of Clinical Endocrinology (AACE), Endocrine Society, European Calcified Tissue Society (ECTS), International Osteoporosis Foundation (IOF), y la National Osteoporosis Foundation (NOF)\nLa gu\u00eda a continuaci\u00f3n se cre\u00f3 para ayudar a los m\u00e9dicos en el manejo de pacientes con osteoporosis que recibir\u00e1n la vacuna contra COVID-19. La pandemia actual requiri\u00f3 de la implementaci\u00f3n de estrategias que han interrumpido la atenci\u00f3n m\u00e9dica para los pacientes con osteoporosis. (1,2) La escacez de datos para proporcionar una gu\u00eda clara es un hecho. Por lo tanto, las siguientes recomendaciones se basan principalmente en la opini\u00f3n de expertos.\nLa osteoporosis en s\u00ed no parece aumentar el riesgo de infecci\u00f3n o complicaciones por COVID-19. Por lo tanto, no es necesario priorizar a los pacientes con osteoporosis para la vacunaci\u00f3n COVID-19 solo en base a esa condici\u00f3n. Cualquier decisi\u00f3n de priorizar a los pacientes con osteoporosis, sin embargo, debe basarse en indicaciones espec\u00edficas de cada pa\u00eds.\nLas medidas generales de salud \u00f3sea (es decir, suplementos de calcio y vitamina D, ejercicios de soporte de peso y mantenimiento de una dieta equilibrada) no deben interrumpirse en el momento de la vacunaci\u00f3n o posteriormente.\nNo hay evidencia de que cualquier tratamiento para la osteoporosis aumente el riesgo o la gravedad de la infecci\u00f3n por COVID-19, altere el curso de la enfermedad o interfiera con la eficacia o el perfil de efectos secundarios de la vacunaci\u00f3n con COVID-19.\nTeniendo en cuenta la disponibilidad limitada de la vacuna COVID-19, es posible que se deba priorizar la dosificaci\u00f3n de la vacuna sobre posibles alteraciones leves en los reg\u00edmenes est\u00e1ndar de osteoporosis (como se detalla a continuaci\u00f3n).\nRecomendaciones de medicaci\u00f3n espec\u00edficas para el manejo de pacientes con osteoporosis en relaci\u00f3n con la vacunaci\u00f3n COVID-19\nBifosfonatos orales [alendronato (Fosamax\u00ae), risedronato (Actonel\u00ae) e ibandronato (Boniva\u00ae)]\nRecomendamos que los bifosfonatos orales se contin\u00faen sin interrupci\u00f3n ni demora en pacientes que reciben la vacuna COVID-19.\nEvidencia\nLos bifosfonatos orales rara vez causan una reacci\u00f3n de fase aguda,(3,4) y no hay evidencia de que la vacuna COVID-19 d\u00e9 lugar a intolerancia a los bifosfonatos o que el tratamiento con bisfosfonatos disminuya la eficacia de la vacuna.\nBifosfonatos intravenosos (IV) [\u00e1cido zoledr\u00f3nico (Reclast\u00ae) e ibandronato (Boniva\u00ae)]\nRecomendamos un intervalo de una semana entre la infusi\u00f3n intravenosa de bisfosfonatos y la vacunaci\u00f3n COVID-19 para poder distinguir entre las posibles reacciones de fase aguda resultantes de la administraci\u00f3n intravenosa de bisfosfonatos o de la vacunaci\u00f3n.\nEvidencia\nEl desarrollo de una reacci\u00f3n inflamatoria posterior a la infusi\u00f3n, particularmente en pacientes sin tratamiento previo, es un efecto secundario bien conocido de la administraci\u00f3n de bisfosfonatos IV, con una duraci\u00f3n media de aproximadamente tres d\u00edas despu\u00e9s de la infusi\u00f3n de \u00e1cido zoledr\u00f3nico.(5,6) Dado que las reacciones de fase aguda son un efecto secundario informado de las vacunas COVID-19 basadas en vectores de adenovirus recombinantes (7) y basadas en ARNm(8), parece prudente escalonar el tiempo de administraci\u00f3n de un bisfosfonato IV y una vacuna COVID-19. No hay datos actuales, sin embargo, que sugieran que la administraci\u00f3n concomitante pueda alterar el perfil de efectos secundarios y/o reducir la eficacia de la vacuna de bisfosfonato IV o COVID-19. Dada la larga vida media biol\u00f3gica esquel\u00e9tica del \u00e1cido zoledr\u00f3nico,(9,10) los pacientes que han recibido tratamiento previo con \u00e1cido zoledr\u00f3nico pueden retrasar las infusiones posteriores durante varios meses si es necesario.\nDenosumab (Prolia\u00ae)\nRecomendamos un intervalo de 4 a 7 d\u00edas entre el tratamiento con denosumab y la vacuna COVID-19 para permitir la posible aparici\u00f3n de reacciones en el lugar de la inyecci\u00f3n con cualquiera de los tratamientos. Alternativamente, el tratamiento con denosumab podr\u00eda administrarse en el brazo contralateral o en un sitio alternativo (abdomen o parte superior del muslo) si es necesario administrarlo concomitantemente con la vacuna COVID-19. Tambi\u00e9n recomendamos que, si bien el tiempo de denosumab puede ajustarse ligeramente para tener en cuenta el tiempo de vacunaci\u00f3n, las inyecciones de denosumab no deben retrasarse m\u00e1s de 7 meses despu\u00e9s de la dosis anterior de denosumab.\nEvidencia\nEl denosumab funciona inhibiendo RANKL. Adem\u00e1s de su papel en la biolog\u00eda de los osteoclastos, RANKL tambi\u00e9n juega un papel importante en la activaci\u00f3n de las c\u00e9lulas T humanas.(11) Los datos actuales no muestran que el denosumab est\u00e9 asociado con un mayor riesgo de infecci\u00f3n por COVID-19 (12) o infecciones respiratorias en pacientes con osteoporosis. (13) El retraso o la interrupci\u00f3n del tratamiento con denosumab se relaciona con un aumento de la resorci\u00f3n \u00f3sea y un aumento del riesgo de fracturas vertebrales, (14) con fracturas notificadas tan pronto como siete meses despu\u00e9s de la \u00faltima inyecci\u00f3n de denosumab. (15)\nTeriparatide (Forteo\u00ae) o abaloparatida (Tymlos\u00ae)\nRecomendamos que se contin\u00fae con teriparatida y abaloparatida en pacientes que reciben la vacuna COVID-19.\nEvidencia\nNinguno de los medicamentos se ha asociado con un mayor riesgo de infecci\u00f3n o efectos inmunomoduladores, ni causa reacciones de fase aguda. Aunque tanto la teriparatida como la abaloparatida pueden inducir reacciones locales en el lugar de la inyecci\u00f3n, generalmente no se administran en el mismo lugar que las vacunas COVID-19 (que generalmente se administran en la parte superior del brazo).\nRomosozumab (Evenity\u00ae)\nRecomendamos un intervalo de 4 a 7 d\u00edas entre la provisi\u00f3n de estas inyecciones, o considerar la inyecci\u00f3n en el abdomen (excepto en un \u00e1rea de dos pulgadas alrededor del ombligo) o en el muslo si se administra de forma concomitante.\nEvidencia\nRomosozumab inhibe la actividad de la esclerostina. Se administra como una inyecci\u00f3n subcut\u00e1nea una vez al mes. No hay evidencia de riesgo de infecci\u00f3n o reacciones de fase aguda con el tratamiento con romosozumab. (16) Se notificaron reacciones en el lugar de la inyecci\u00f3n en la parte superior del brazo (dolor, hinchaz\u00f3n y eritema) como posibles efectos secundarios de la vacunaci\u00f3n con romosozumab y COVID-19. (7,8 ,16)\nRaloxifeno\nRecomendamos que se contin\u00fae con raloxifeno en pacientes que reciben la vacuna COVID-19.\nEvidencia\nNo se conoce interacci\u00f3n entre raloxifeno y las vacunas COVID-19. La terapia con raloxifeno no causa una reacci\u00f3n de fase aguda.\nReferencias\n-\nYu EW, Tsourdi E, Clarke BL, Bauer DC, Drake MT. Osteoporosis management in the era of COVID-19. J Bone Miner Res. 2020;35(6):1009-13.\n-\nNapoli N, Elderkin AL, Kiel DP, Khosla S. Managing fragility fractures during the COVID-19 pandemic. Nat Rev Endocrinol. 2020;16(9):467-8.\n-\nHagino H, Kishimoto H, Ohishi H, Horii S, Nakamura T. Efficacy, tolerability and safety of once-monthly administration of 75mg risedronate in Japanese patients with involutional osteoporosis: a comparison with a 2.5mg once-daily dosage regimen. Bone. 2014;59:44-52.\n-\nSaag K, Lindsay R, Kriegman A, Beamer E, Zhou W. A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density. Bone. 2007;40(5):1238-43.\n-\nReid IR, Gamble GD, Mesenbrink P, Lakatos P, Black DM. Characterization of and risk factors for the acute-phase response after zoledronic acid. J Clin Endocrinol Metab. 2010; 95(9):4380-7.\n-\nReclast\u00ae (zoledronic acid) Injection Full Prescribing Information:\n[https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021817s027lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021817s027lbl.pdf)\n-\nZhu FC, Li YH, Guan XH, et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet. 2020;395(10240):1845-54.\n-\nBaden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403-16.\n-\nBlack DM, Reid IR, Boonen S, et al. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res. 2012;27(2):243-54.\n-\nBlack DM, Reid IR, Cauley JA, et al. The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res. 2015;30(5):934-44.\n-\nSobacchi C, Menale C, Villa A. The RANKL-RANK axis: a bone to thymus round trip. Front Immunol. 2019;10:629.\n-\nBlanch- Rubi\u00f3 J, Soldevila-Domenech N, T\u00edo L, et al. Influence of anti-osteoporosis treatments on the incidence of COVID-19 in patients with non-inflammatory rheumatic conditions. Aging (Albany NY). 2020;12(20):19923-37.\n-\nDirk-Cohen T, Rosenberg D, Avni T, Shepshelovich D, Tsvetov G, Gafter-Gvili A. Risk for infections during treatment with denosumab for osteoporosis: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2020;105(5):dgz322.\n-\nTsourdi E, Zillikens MC, Meier C, et al. Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS. J Clin Endocrinol Metab. 2020;doi: 10.1210/clinem/dgaa756 [Epub ahead of print].\n-\nGonzalez-Rodriguez E, Aubry-Rozier B, Stoll D, Zaman K, Lamy O. Sixty spontaneous vertebral fractures after denosumab discontinuation in 15 women with early-stage breast cancer under aromatase inhibitors. Breast Cancer Res Treat. 2020;179(1):153-9.\n-\nKaveh S, Hosseinifard H, Ghadimi N, Vojdanian M, Aryankhesal A. Efficacy and safety of romosozumab in treatment for low bone mineral density: a systematic review and meta-analysis. Clin Rheumatol. 2020;39(11):3261-76.", "language": null, "image": "https://www.osteoporosis.foundation/sites/iofbonehealth/files/styles/social_large/public/images/2021-03/woman-vaccine_002.jpg?h=2d948865&itok=CV2zHWWB", "pagetype": "blogposting", "links": ["#main-content", "/", "/about-us?overridden_route_name=entity.node.canonical&base_route_name=entity.node.canonical&page_manager_page=node_view&page_manager_page_variant=node_view-panels_variant-0&page_manager_page_variant_weight=0#About-IOF", "/about-us?overridden_route_name=entity.node.canonical&base_route_name=entity.node.canonical&page_manager_page=node_view&page_manager_page_variant=node_view-panels_variant-0&page_manager_page_variant_weight=0#the-board", "/about-us?overridden_route_name=entity.node.canonical&base_route_name=entity.node.canonical&page_manager_page=node_view&page_manager_page_variant=node_view-panels_variant-0&page_manager_page_variant_weight=0#executive-committee", "/about-us?overridden_route_name=entity.node.canonical&base_route_name=entity.node.canonical&page_manager_page=node_view&page_manager_page_variant=node_view-panels_variant-0&page_manager_page_variant_weight=0#the-regional-representation", "/our-network/the-committees?overridden_route_name=entity.node.canonical&base_route_name=entity.node.canonical&page_manager_page=node_view&page_manager_page_variant=node_view-panels_variant-0&page_manager_page_variant_weight=0", "/about-us?overridden_route_name=entity.node.canonical&base_route_name=entity.node.canonical&page_manager_page=node_view&page_manager_page_variant=node_view-panels_variant-0&page_manager_page_variant_weight=0#the-staff", "/about-us?overridden_route_name=entity.node.canonical&base_route_name=entity.node.canonical&page_manager_page=node_view&page_manager_page_variant=node_view-panels_variant-0&page_manager_page_variant_weight=0#annual-report", "/about-us?overridden_route_name=entity.node.canonical&base_route_name=entity.node.canonical&page_manager_page=node_view&page_manager_page_variant=node_view-panels_variant-0&page_manager_page_variant_weight=0#contact-us", "https://www.osteoporosis.foundation/logo-and-brand-guidelines", "/what-we-do/science-and-research?overridden_route_name=entity.node.canonical&base_route_name=entity.node.canonical&page_manager_page=node_view&page_manager_page_variant=node_view-panels_variant-0&page_manager_page_variant_weight=0#latest-news", "/what-we-do/science-and-research?overridden_route_name=entity.node.canonical&base_route_name=entity.node.canonical&page_manager_page=node_view&page_manager_page_variant=node_view-panels_variant-0&page_manager_page_variant_weight=0#capture-the-fracture", "/what-we-do/science-and-research?overridden_route_name=entity.node.canonical&base_route_name=entity.node.canonical&page_manager_page=node_view&page_manager_page_variant=node_view-panels_variant-0&page_manager_page_variant_weight=0#latest-projects", "/what-we-do/science-and-research?overridden_route_name=entity.node.canonical&base_route_name=entity.node.canonical&page_manager_page=node_view&page_manager_page_variant=node_view-panels_variant-0&page_manager_page_variant_weight=0#working-groups", "/what-we-do/science-and-research?overridden_route_name=entity.node.canonical&base_route_name=entity.node.canonical&page_manager_page=node_view&page_manager_page_variant=node_view-panels_variant-0&page_manager_page_variant_weight=0#osteoporosis-essentials", "/what-we-do/science-and-research?overridden_route_name=entity.node.canonical&base_route_name=entity.node.canonical&page_manager_page=node_view&page_manager_page_variant=node_view-panels_variant-0&page_manager_page_variant_weight=0#journals", "/what-we-do/science-and-research?overridden_route_name=entity.node.canonical&base_route_name=entity.node.canonical&page_manager_page=node_view&page_manager_page_variant=node_view-panels_variant-0&page_manager_page_variant_weight=0#frax", "/what-we-do/science-and-research?overridden_route_name=entity.node.canonical&base_route_name=entity.node.canonical&page_manager_page=node_view&page_manager_page_variant=node_view-panels_variant-0&page_manager_page_variant_weight=0#awards", "/what-we-do/policy-and-advocacy?overridden_route_name=entity.node.canonical&base_route_name=entity.node.canonical&page_manager_page=node_view&page_manager_page_variant=node_view-panels_variant-0&page_manager_page_variant_weight=0#latest-news", "/what-we-do/policy-and-advocacy?overridden_route_name=entity.node.canonical&base_route_name=entity.node.canonical&page_manager_page=node_view&page_manager_page_variant=node_view-panels_variant-0&page_manager_page_variant_weight=0#world-osteoporosis-day", "/what-we-do/policy-and-advocacy?overridden_route_name=entity.node.canonical&base_route_name=entity.node.canonical&page_manager_page=node_view&page_manager_page_variant=node_view-panels_variant-0&page_manager_page_variant_weight=0#global-patient-charter", "/what-we-do/policy-and-advocacy?overridden_route_name=entity.node.canonical&base_route_name=entity.node.canonical&page_manager_page=node_view&page_manager_page_variant=node_view-panels_variant-0&page_manager_page_variant_weight=0#improve-your-knowledge", "/what-we-do/policy-and-advocacy?overridden_route_name=entity.node.canonical&base_route_name=entity.node.canonical&page_manager_page=node_view&page_manager_page_variant=node_view-panels_variant-0&page_manager_page_variant_weight=0#iof-compendium", "/what-we-do/meetings-events", "/educational-hub?overridden_route_name=entity.node.canonical&base_route_name=entity.node.canonical&page_manager_page=node_view&page_manager_page_variant=node_view-panels_variant-0&page_manager_page_variant_weight=0#from--what-we-do", "/educational-hub?overridden_route_name=entity.node.canonical&base_route_name=entity.node.canonical&page_manager_page=node_view&page_manager_page_variant=node_view-panels_variant-0&page_manager_page_variant_weight=0#main", "/patients?overridden_route_name=entity.node.canonical&base_route_name=entity.node.canonical&page_manager_page=node_view&page_manager_page_variant=node_view-panels_variant-0&page_manager_page_variant_weight=0", "/patients?overridden_route_name=entity.node.canonical&base_route_name=entity.node.canonical&page_manager_page=node_view&page_manager_page_variant=node_view-panels_variant-0&page_manager_page_variant_weight=0#osteoporosis-riskcheck", "/patients/about-osteoporosis", "/patients/prevention", "/patients/diagnosis", "/patients/treatment", "https://www.osteoporosis.foundation/educational-hub/material/patient-resources", "/patients?overridden_route_name=entity.node.canonical&base_route_name=entity.node.canonical&page_manager_page=node_view&page_manager_page_variant=node_view-panels_variant-0&page_manager_page_variant_weight=0#did-you-know", "/patients?overridden_route_name=entity.node.canonical&base_route_name=entity.node.canonical&page_manager_page=node_view&page_manager_page_variant=node_view-panels_variant-0&page_manager_page_variant_weight=0#world-osteoporosis-day", "/patients?overridden_route_name=entity.node.canonical&base_route_name=entity.node.canonical&page_manager_page=node_view&page_manager_page_variant=node_view-panels_variant-0&page_manager_page_variant_weight=0#they-live-with-osteoporosis", "/patients?overridden_route_name=entity.node.canonical&base_route_name=entity.node.canonical&page_manager_page=node_view&page_manager_page_variant=node_view-panels_variant-0&page_manager_page_variant_weight=0#who-is-fighting-with-us", "/patients?overridden_route_name=entity.node.canonical&base_route_name=entity.node.canonical&page_manager_page=node_view&page_manager_page_variant=node_view-panels_variant-0&page_manager_page_variant_weight=0#global-patient-charter", "/patients?overridden_route_name=entity.node.canonical&base_route_name=entity.node.canonical&page_manager_page=node_view&page_manager_page_variant=node_view-panels_variant-0&page_manager_page_variant_weight=0#newsletter-patient", "/health-professionals", "/health-professionals?overridden_route_name=entity.node.canonical&base_route_name=entity.node.canonical&page_manager_page=node_view&page_manager_page_variant=node_view-panels_variant-0&page_manager_page_variant_weight=0#make-sure-you-are-up-to-date", "/health-professionals/about-osteoporosis", "/health-professionals/prevention", "/health-professionals/diagnosis", "/health-professionals/treatment", "/health-professionals/fragility-fractures", "/health-professionals/fragility-fractures/epidemiology", "/health-professionals/fragility-fractures/assessing-vertebral-fractures", "/health-professionals/fragility-fractures/treatment", "/health-professionals/fragility-fractures/models-of-care", "/health-professionals/fragility-fractures/falls-prevention", "/health-professionals?overridden_route_name=entity.node.canonical&base_route_name=entity.node.canonical&page_manager_page=node_view&page_manager_page_variant=node_view-panels_variant-0&page_manager_page_variant_weight=0#facts-statistics", "https://www.osteoporosis.foundation/capture-the-fracture", "/what-we-do/science-and-research?overridden_route_name=entity.node.canonical&base_route_name=entity.node.canonical&page_manager_page=node_view&page_manager_page_variant=node_view-panels_variant-0&page_manager_page_variant_weight=0#frax", "https://www.osteoporosis-essentials.org/", "/what-we-do/meetings-events", "https://www.osteoporosis.foundation/what-we-do/science-and-research/working-groups", "/health-professionals/articles-and-position-papers", "/educational-hub?overridden_route_name=entity.node.canonical&base_route_name=entity.node.canonical&page_manager_page=node_view&page_manager_page_variant=node_view-panels_variant-0&page_manager_page_variant_weight=0#from--health-professionals", "/health-professionals/research-tools?overridden_route_name=entity.node.canonical&base_route_name=entity.node.canonical&page_manager_page=node_view&page_manager_page_variant=node_view-panels_variant-0&page_manager_page_variant_weight=0", "/educational-hub/material/patient-resources", "/health-professionals?overridden_route_name=entity.node.canonical&base_route_name=entity.node.canonical&page_manager_page=node_view&page_manager_page_variant=node_view-panels_variant-0&page_manager_page_variant_weight=0#journals", "/health-professionals?overridden_route_name=entity.node.canonical&base_route_name=entity.node.canonical&page_manager_page=node_view&page_manager_page_variant=node_view-panels_variant-0&page_manager_page_variant_weight=0#skeletal-rare-disorders", "https://www.osteoporosis.foundation/osteoporosis-and-covid19", "/policy-makers", "/policy-makers?overridden_route_name=entity.node.canonical&base_route_name=entity.node.canonical&page_manager_page=node_view&page_manager_page_variant=node_view-panels_variant-0&page_manager_page_variant_weight=0#burden-of-osteoporosis", "/policy-makers?overridden_route_name=entity.node.canonical&base_route_name=entity.node.canonical&page_manager_page=node_view&page_manager_page_variant=node_view-panels_variant-0&page_manager_page_variant_weight=0#facts-statistics", "/policy-makers?overridden_route_name=entity.node.canonical&base_route_name=entity.node.canonical&page_manager_page=node_view&page_manager_page_variant=node_view-panels_variant-0&page_manager_page_variant_weight=0#fracture-liaison-services", "/policy-makers?overridden_route_name=entity.node.canonical&base_route_name=entity.node.canonical&page_manager_page=node_view&page_manager_page_variant=node_view-panels_variant-0&page_manager_page_variant_weight=0#global-patient-charter", "/policy-makers?overridden_route_name=entity.node.canonical&base_route_name=entity.node.canonical&page_manager_page=node_view&page_manager_page_variant=node_view-panels_variant-0&page_manager_page_variant_weight=0#policy-reports-audits", "/policy-makers?overridden_route_name=entity.node.canonical&base_route_name=entity.node.canonical&page_manager_page=node_view&page_manager_page_variant=node_view-panels_variant-0&page_manager_page_variant_weight=0#iof-alliances", "/policy-makers?overridden_route_name=entity.node.canonical&base_route_name=entity.node.canonical&page_manager_page=node_view&page_manager_page_variant=node_view-panels_variant-0&page_manager_page_variant_weight=0#world-osteoporosis-day", "/policy-makers?overridden_route_name=entity.node.canonical&base_route_name=entity.node.canonical&page_manager_page=node_view&page_manager_page_variant=node_view-panels_variant-0&page_manager_page_variant_weight=0#they-live-with-osteoporosis", "/our-network", "/our-network/the-committees?overridden_route_name=entity.node.canonical&base_route_name=entity.node.canonical&page_manager_page=node_view&page_manager_page_variant=node_view-panels_variant-0&page_manager_page_variant_weight=0", "/our-network?overridden_route_name=entity.node.canonical&base_route_name=entity.node.canonical&page_manager_page=node_view&page_manager_page_variant=node_view-panels_variant-0&page_manager_page_variant_weight=0#fracture-liaison-services", "/our-network?overridden_route_name=entity.node.canonical&base_route_name=entity.node.canonical&page_manager_page=node_view&page_manager_page_variant=node_view-panels_variant-0&page_manager_page_variant_weight=0#latest-news", "/our-network?overridden_route_name=entity.node.canonical&base_route_name=entity.node.canonical&page_manager_page=node_view&page_manager_page_variant=node_view-panels_variant-0&page_manager_page_variant_weight=0#iof-alliances", "/our-network?overridden_route_name=entity.node.canonical&base_route_name=entity.node.canonical&page_manager_page=node_view&page_manager_page_variant=node_view-panels_variant-0&page_manager_page_variant_weight=0#corporate-partners", "/our-network?overridden_route_name=entity.node.canonical&base_route_name=entity.node.canonical&page_manager_page=node_view&page_manager_page_variant=node_view-panels_variant-0&page_manager_page_variant_weight=0#newsletter-our-network", "https://www.osteoporosis.foundation/our-network/universities", "https://capturethefracture.org/", "http://www.worldosteoporosisday.org/", "https://www.osteoporosis-essentials.org/", "/about-us/regional-representation--latin-america-region", "#iof-page", "/", "/", "/news?overridden_route_name=entity.node.canonical&base_route_name=entity.node.canonical&page_manager_page=node_view&page_manager_page_variant=node_view-panels_variant-0&page_manager_page_variant_weight=0", "https://www.facebook.com/iofbonehealth", "https://twitter.com/iofbonehealth", "https://www.linkedin.com/company/international-osteoporosis-foundation", "https://www.instagram.com/international_osteoporosis/", "https://www.youtube.com/iofbonehealth", "/donate", "https://www.addtoany.com/share#url=https%3A%2F%2Fwww.osteoporosis.foundation%2Fnews%2Forientacion-conjunta-sobre-la-vacunacion-contra-covid-19-y-el-manejo-de-la-osteoporosis&title=Node%20view", "/", "/news?overridden_route_name=entity.node.canonical&base_route_name=entity.node.canonical&page_manager_page=node_view&page_manager_page_variant=node_view-panels_variant-0&page_manager_page_variant_weight=0", null, "/news-latam", "/news/iof-y-conameger-se-unen-para-fomentar-la-prevencion-secundaria-de-fracturas-20210303-0820", "/news/registro-habilitado-para-el-meet-expert-online-2021-20210317-1055", "https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021817s027lbl.pdf", "/news-room/tags/latin-america", "", "tel:+41229940100", "mailto:info@osteoporosis.foundation", "https://www.facebook.com/iofbonehealth", "https://twitter.com/iofbonehealth", "https://www.linkedin.com/company/international-osteoporosis-foundation", "https://www.instagram.com/international_osteoporosis/", "https://www.youtube.com/iofbonehealth", "/cookie-policy", "/privacy-policy"]}